Composition containing cyclic peptide compound and surfactant

A composition comprising a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a surfactant,

• wherein the surfactant is represented by any one of the following general formulae (a1) to (a3):
• wherein R1 is C1 to C6 alkyl or C3 to C8 cycloalkyl C1 to C6 alkyl;
• P1 is C1 to C6 alkyl;
• R2 is C1 to C6 alkyl;
• R3 is hydrogen, or forms a 4- to 7-membered saturated heterocyclic ring together with P3, a carbon atom bonded to R3, and a nitrogen atom bonded to P3;
• P3 is C1 to C6 alkyl or C3 to C8 cycloalkyl except when R3 and P3 form a 4- to 7-membered saturated heterocyclic ring;
• P4 is C1 to C6 alkyl;
• R5 is benzyl optionally substituted by one or more groups selected from the group consisting of C1 to C6 alkyls, C1 to C6 haloalkyls, and C3 to C8 cycloalkyls;
• P6 is C1 to C6 alkyl;
• R7 is phenethyl optionally substituted by one or more groups selected from the group consisting of halogens, C1 to C6 haloalkyls, and C1 to C6 alkoxys;
• R8 forms a 4- to 7-membered saturated heterocyclic ring together with P8, a carbon atom bonded to R8, and a nitrogen atom bonded to P8, the 4- to 7-membered saturated heterocyclic ring being optionally substituted by a C1 to C6 alkoxy;
• R9 forms a 3- to 8-membered alicyclic ring together with Q9 and a carbon atom bonded to R9 and Q9, the 3- to 8-membered alicyclic ring being optionally substituted by one or more C1 to C6 alkyls;
• P9 is hydrogen or C1 to C6 alkyl;
• R10 is C1 to C6 alkyl or C3 to C8 cycloalkyl;
• P10 is C1 to C6 alkyl;
• R11 is di-C1 to C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl;
• and
• P11 is C1 to C6 alkyl,
• wherein RS1 represents a saturated or unsaturated, linear hydrocarbon group having 5 or more and 13 or less carbon atoms which may have a substituent, X represents sodium or potassium, and Y represents a group represented by the following formula (a4) or a stereoisomer thereof,
• wherein
• represents a bond.

A composition to be used in combination with a surfactant,

• wherein the surfactant is represented by any one of the following general formulae (a1) to (a3),
• the composition comprising a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof:
• wherein RS1 represents a saturated or unsaturated, linear hydrocarbon group having 5 or more and 13 or less carbon atoms which may have a substituent, X represents sodium or potassium, and Y represents a group represented by the following formula (a4) or a stereoisomer thereof,
• wherein
• represents a bond,
• wherein R1 is C1 to C6 alkyl or C3 to C8 cycloalkyl C1 to C6 alkyl;
• P1 is C1 to C6 alkyl;
• R2 is C1 to C6 alkyl;
• R3 is hydrogen, or forms a 4- to 7-membered saturated heterocyclic ring together with P3, a carbon atom bonded to R3, and a nitrogen atom bonded to P3;
• P3 is C1 to C6 alkyl or C3 to C8 cycloalkyl except when R3 and P3 form a 4- to 7-membered saturated heterocyclic ring;
• P4 is C1 to C6 alkyl;
• R5 is benzyl optionally substituted by one or more groups selected from the group consisting of C1 to C6 alkyls, C1 to C6 haloalkyls, and C3 to C8 cycloalkyls;
• P6 is C1 to C6 alkyl;
• R7 is phenethyl optionally substituted by one or more groups selected from the group consisting of halogens, C1 to C6 haloalkyls, and C1 to C6 alkoxys;
• R8 forms a 4- to 7-membered saturated heterocyclic ring together with P8, a carbon atom bonded to R8, and a nitrogen atom bonded to P8, the 4- to 7-membered saturated heterocyclic ring being optionally substituted by a C1 to C6 alkoxy;
• R9 forms a 3- to 8-membered alicyclic ring together with Q9 and a carbon atom bonded to R9 and Q9, the 3- to 8-membered alicyclic ring being optionally substituted by one or more C1 to C6 alkyls;
• P9 is hydrogen or C1 to C6 alkyl;
• R10 is C1 to C6 alkyl or C3 to C8 cycloalkyl;
• P10 is C1 to C6 alkyl;
• R11 is di-C1 to C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl;
• and
• P11 is C1 to C6 alkyl.

A method for improving the absorption of a compound represented by general formula (1),

• the method comprising incorporating, in a same composition, a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a surfactant selected from the group consisting of lauroyl-L-carnitine, sodium caprylate, sodium lauryl sulfate, and sodium N-(8-[2-hydroxybenzoyl]amino)caprylate:
• wherein R1 is C1 to C6 alkyl or C3 to C8 cycloalkyl C1 to C6 alkyl;
• P1 is C1 to C6 alkyl;
• R2 is C1 to C6 alkyl;
• R3 is hydrogen, or forms a 4- to 7-membered saturated heterocyclic ring together with P3, a carbon atom bonded to R3, and a nitrogen atom bonded to P3;
• P3 is C1 to C6 alkyl or C3 to C8 cycloalkyl except when R3 and P3 form a 4- to 7-membered saturated heterocyclic ring;
• P4 is C1 to C6 alkyl;
• R5 is benzyl optionally substituted by one or more groups selected from the group consisting of C1 to C6 alkyls, C1 to C6 haloalkyls, and C3 to C8 cycloalkyls;
• P6 is C1 to C6 alkyl;
• R7 is phenethyl optionally substituted by one or more groups selected from the group consisting of halogens, C1 to C6 haloalkyls, and C1 to C6 alkoxys;
• R8 forms a 4- to 7-membered saturated heterocyclic ring together with P8, a carbon atom bonded to R8, and a nitrogen atom bonded to P8, the 4- to 7-membered saturated heterocyclic ring being optionally substituted by a C1 to C6 alkoxy;
• R9 forms a 3- to 8-membered alicyclic ring together with Q9 and a carbon atom bonded to R9 and Q9, the 3- to 8-membered alicyclic ring being optionally substituted by one or more C1 to C6 alkyls;
• P9 is hydrogen or C1 to C6 alkyl;
• R10 is C1 to C6 alkyl or C3 to C8 cycloalkyl;
• P10 is C1 to C6 alkyl;
• R11 is di-C1 to C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl;
• and
• P11 is C1 to C6 alkyl.